medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Using Machine Learning to assess Covid-19
risks
Srikanth Muthya , Renjith S Nair, Dr Thanga Prabhu Arokiaswamy, Anusha Prakash
Author Affiliations: Cohere Med Inc.(Srikanth Muthya, Renjith S Nair, Dr Thanga Prabhu
Arokiaswamy, Anusha Prakash)
Corresponding Author: Srikanth Muthya, CEO and President, Cohere Med Inc.
Srikanth.Muthya@gmail.com telephone (+91) 9845191930
No of words: 3050

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

ABSTRACT:
IMPORTANCE:
Identifying potential Covid-19 patients in the general population is a huge challenge at the moment. Given the
low availability of infected Covid-19 patients clinical data, it is challenging to understand and comprehend similar
and complex patterns in these symptomatic patients. Laboratory testing for Covid19 antigen with RT-PCR |
(Reverse Transcriptase) is not possible or economical for whole populations.

OBJECTIVE:
To develop a Covid risk stratifier model that classifies people into different risk cohorts, based on their symptoms
and validate the same.

DESIGN:
Analysis of Covid cases across Wuhan and New York were done to identify the course of these cases prior to
being symptomatic and being hospitalised for the infection. A dataset based on these statistics were generated and
was then fed into an unsupervised learning algorithm to reveal patterns and identify similar groups of people in
the population. Each of these cohorts were then classified and identified into three risk levels that were validated
against the real world cases and studies.

SETTING:
The study is based on general population.

PARTICIPANTS:
The adult population were considered for the analysis, development and validation of the model

RESULTS:
Of 1 million observations generated, 20% of them exhibited Covid symptoms and patterns, and 80% of them
belonged to the asymptomatic and non-infected group of people. Upon clustering, three clinically obvious clusters
were obtained, out of which the Cluster A had 20% of the symptomatic cases that were classified into one cohort,
the other two cohorts, Cluster B had people with no symptoms but with high number of comorbidities and Cluster
C had people with few leading indicators for the infection with few comorbidities. This was then validated against
300 participants whose data we collected as a part of a research study through our Covid-research tool and about
92% of them were classified correctly.

CONCLUSION:
A model was developed and validated that classifies people into Covid risk categories based on their symptoms.
This can be used to monitor and track cases that rapidly transition into being symptomatic which eventually get
tested positive for the infection in order to initiate early medical interventions.

KEYWORDS: Covid-19, Synthetic Data, Patient Clustering, Unsupervised Learning, Risk Classification.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

INTRODUCTION:
Covid19 has surprised the world with its infectivity and rapid spread globally causing massive loss of life and
livelihoods. The right way to tackle this pandemic is to act quickly in identifying those at risk and treat patients
early. Identifying and tracking symptoms of Covid infected patients is challenging today as new insights of its
etiologic, pathology, public health impact, epidemiology, treatment options, vaccination etc. are emerging
continuously with its global spread.
Machine learning has been extensively used in biomedical and medical sciences today to help in improving
hospital outcomes, by effective early interventions that lead to improved prognosis. Data can be a powerful tool
to analyse, interpret and build predictive models around them to support improved health care, if validated and
analysed rightly. A scientific approach of using these techniques, can perfectly complement the clinical diagnostic
and treatment protocols.
Getting access to datasets that capture the trends in the general population from being healthy to acquiring the
infection and in-hospital prognosis phase is quite challenging and isn‚Äôt open source for the public due to obvious
security and privacy concerns at the moment. Nevertheless, current investigations and studies are available that
encapsulate most of the common statistics and symptoms of Covid patients. Using this, our proposed method
captures these statistics along with some clinical background and generates a dataset on which we intend to apply
an unsupervised learning algorithm to identify patterns and classify them into risk cohorts.
In predictive modelling, the term ‚ÄúUnsupervised Learning‚Äù refers to instances where the data does not have a label
associated with it. Getting labels on data can be a very expensive process in terms of money, time and manpower.
In such cases the knowledge is inferred from the data itself by applying clustering algorithms to find hidden,
similar patterns and groups by some exploratory analysis. In our method, we have tried to infer patterns in different
cohorts of people and label their Covid risk levels through analysis and further validation of the same.
In cases where the data isn't available, one proven method in the healthcare space is to generate faux data through
good clinical reasoning and validation. The data set is usually generated using a logic based algorithm that captures
human knowledge about the subject along with current research and studies with some evidence. Covid based
research has evidently increased since the pandemic has struck and related resources are available extensively
today, and this method has tried to capture these studies into an interpretable form for analysis and categorization
of different risk cohorts that were validated against current data. This model can be used to identify risk levels,
based on which cohort they belong to or transition into, over a period of time.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

RELATED WORK:
Creating synthetic datasets in healthcare is predominantly increasing because of the existing challenges in
healthcare systems to record information in EHR and EMR formats and even if this isn‚Äôt a hindrance, security and
privacy controls laws on these data are very stringent that it becomes hard to get access to. Nevertheless, synthetic
data sets can be evolved to a better real world representation without compromising on the quality of the clinical
information but also can help avoiding privacy clauses and concerns around them. [1]
One such notable example is GAN‚Äôs (Generative Adversarial Network) in the deep learning research space that
generates completely synthetic data with real world logics. medGAN(Choi et al)[2] is an algorithm that generated
realistic synthetic EHR‚Äôs that were high dimensional and discrete in nature using GAN‚Äôs and autoencoders. The
RCGAN[3] is another interesting work that generated high dimensional realistic synthetic time series datasets using
Recurrent GAN‚Äôs. Most of the GAN techniques applied in healthcare settings had some or very little real world
data that was fed into GAN‚Äôs which isn‚Äôt the case with our problem statement. The availability of COVID patient
records at absolutely zero today. Two drawbacks of using GAN‚Äôs are validation and poor interpretability in
assessing why some samples are created and this makes it hard to implement.
Laura et al.(2018)[4] used Naive Bayes clustering methods to generate realistic datasets taking MIMIC III as a
baseline and had much better results compared to medGAN[2].
One very similar approach as ours as is, of Chen et al.(2019)[5]which generated more than a million ‚Äúsynthetic
residents‚Äù by an algorithm named Synthea, also called as Synthetic mass that represented residential population
around Massachusetts, USA and mimicked the statistics of the population including their demographics,
vaccinations, medical visits and comorbidities. This was also compared and validated with the original population
around the city.
Another notable work is of Harvard Dataverse, which has 10,000 completely synthetic datasets of patients
generated from software called Synthea that was mentioned previously.[7]
Mahmoud et al.(2017) used K-means clustering to predict patient outcomes in elderly patients[19].Hany et al.(2019)
have summarized how clustering techniques and pattern identification in AD patients(Alzheimer‚Äôs disease), from
early to last stages of the disease can be effective in healthcare[20]. Lio (et al.) applied clustering techniques to find
patterns in end stage renal disease patients who initiated Hemodialysis [22].

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

PROPOSED METHOD:
I. PROBLEM ASSESSMENT:
Coronavirus is known to progress in some infected patients, affecting the vital organs of the body rapidly. Not
everybody will experience similar symptoms, it varies from person to person and a majority remain asymptomatic.
It becomes challenging to identify such patterns in the general population. If the population is tracked for
symptoms constantly, monitored and assessed for infection, then identifying people who are likely to be infected
can initiate early interventions.

II. FAUX DB GENERATION
To understand complex patterns and symptoms in infected cases, A real world dataset explaining clinical
conditions during the asymptomatic case is required to do any research and build predictive models around it.
Obtaining such historical clinical information of cases can be very expensive, time consuming and sensitive to be
made open source to the public. Often, even if this kind of data existed, clinical records have missing gaps and
acute information that aren‚Äôt adequate enough to draw conclusions from . With this challenge of obtaining clinical
data by conventional methods, generating a ‚Äúsynthetic but convincing‚Äù dataset to understand the patterns in
symptomatic cases with current evidence and studies is the need of the hour. Studies have shown that generating
synthetic clinical dataset is a promising and a plausible approach to take in such scenarios that can solve current
problems.
Using statistical studies related to Covid infected cases across cities of Wuhan, China and New York, USA a
dataset was generated that fit across these populations and describes them well enough to work on. Although the
statistics of infected cases across the globe are contrasting to one another, an effort was made to capture the
recurring patterns and similarities in both the cities that normalises this difference to an acceptable level. The
reason why cases across these cities were chosen in particular, is primarily due to the fact that they have the most
number of cases with a huge population and validation of our dataset would use this as a baseline and for future
studies.
Covid19 In-hospital admission information was considered from the period March 1, 2020 until April 4, 2020
from an investigation conducted in New York[8], which was the epicenter of Covid cases in the United States. This
investigation consisted of a total of 5700 participants who were diagnosed with the infection and had received
treatment for the same. Statistics of these patients included the comorbidities, symptoms, age, gender ,race and
more. Similarly, the characteristics from Wuhan, which happens to be the world‚Äôs epicentre for the virus, were
studied, from the period December 8,2019 to March 8,2020.[9] This study investigated the trends in the spread of
the virus, and symptoms. They were studied across different cohorts of population that were classified into mild,
moderate and severe with respect to the infection. It also captured similar characteristics of that of the former
study mentioned.
Both of these studies were compared against each other in terms of infected population‚Äôs statistics and were found
to be contrasting at few places with different numbers in demographics like gender and age. The common
characteristics were found to be comorbidities and the early symptoms of the infection.
We tried minimising these differences and came up with numbers that equated instances from both the
investigations and fairly generalised the infection trends and symptoms for a general population. We do not intend
to build a universal data set that represents the global population. Our interest is to capture major symptomatic
and infection prone populations based on the studies till date and simulate the same.
The idea behind generating synthetic dataset begins with exploiting freely available information regarding the
statistics, prevalence and incidence of this infection. From these statistics, we can get a fair picture regarding the
demographics, and prevalence of symptoms and comorbidities in the infected population. The synthetic data was
generated by GRiSER‚Äôs method [21].Fig 1 explains the approach to build our dataset from open source information
and clinical knowledge.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

III. DATA DESCRIPTION
The features we considered were symptoms observed in infected patients and comorbidities. We did not consider
age as a feature since we believe ‚Äúcovid19 is a de novo disease. initially thought to affect elders predominantly.
With time, other age groups were also affected but mechanism is poorly understood. Age does not appear to be a
primary factor in getting infected or disease progression‚Äù. We define ‚ÄúCovid criteria met‚Äù definition based on
higher incidence and prevalence of certain symptoms associated with this virus that is likely to be experienced by
the host during the initial stages of the infection.[9] We also identified few leading indicators or signs that were
likely to occur in some symptomatic populations. For example, Diarrhea, nausea ,conjunctivitis and loss of taste
and smell[11] were found to be in the very early stages of the infection. Also, Travel history along with flu-like
symptoms can be a strong indicator of the infection. The Covid criteria met definition was curated from observed
symptoms in infected patients globally and coronavirus studies.[8][9][10] Table 1 explains the Covid criteria met
definition and Table 2 explains the features we have identified and considered as a part of our study.
We generated over 1 Million records that captured the above statistics and demographics with categorical
information(Boolean values). The description of the data generated is explained in Table 3.

IV. CLUSTERING APPROACH
Clustering analysis is used on unlabelled dataset to learn different cohorts and patterns in the data. Most popular
clustering algorithm used in healthcare applications is the K-means clustering algorithm. This is used when we
have numerical and continuous clinical data[12]. K-means algorithm[13] groups similar data points together and
identifies the underlying patterns within them. It uses distance based metrics to group data into K different clusters
by calculating K different centroids(An imaginary location that represents the center of the cluster) and assigning
every data point to the nearest centroid.
Applying K-means on our data does not make sense since, Euclidean distance isn‚Äôt the right distance metric when
we have a dataset with categorical features. Rather, we need to capture the dissimilarity measure between our data
points. Here is when we use the K-Modes algorithm, which is a slight extension of K-means, except that it
quantifies the dissimilarity between two data points rather than compute distances.[14][15] The K-Modes algorithm
can be explained on a high level
(

d1(X,Y)=!)*+ d(Xj, Yj)
where (Xj,Yj) is defined as
0 (Xj = Yj) ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..
(Xj,Yj)= ,
(1)
1 (Xj ‚â† Yj)
5

C(Q) = !6*+(Zùëñ, Qùëñ)

‚Ä¶‚Ä¶‚Ä¶..

(2)

where Z is the categorical variables ranging from A0,A1...An and Zi is the ith element and Qi is near cluster center.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Listing 1. Explains high level algorithm for K-modes Clustering.
K-MODES ALGORITHM
Input: Data of dimension N*X, N being the number of observations and X being the number of features.
K : No of clusters.
Step 1:Randomly select K different modes from the input data such that Ci,j = 1,2..K.
Step 2: Compare each data point in the cluster to each data point from the input data set.
Step 3: Add 1 for every dissimilarity encountered and 0 for equal values as shown in equation (1)
Step 4: Assign each individual to the closest centroid. (2)
Step 5: Calculate mode for each feature for every centroid.
Step 6: Repeat steps 2 to 5 until no changes are obtained in the data assignment to the centroids.

IV a. CHOOSING OPTIMAL K VALUE
Choosing the optimal K or number of cluster values is a very important step in clustering. We applied silhouette
scoring and cost analysis to arrive at our K value. Silhouette score is a measure of similarity between a data point
and its own clusters[16]. The best value is supposedly close to 1 and negative values would indicate data points
assigned to wrong clusters. The K is chosen based on the high silhouette coefficient value obtained after iterating
through various K values. The silhouette coefficient is usually measured based on the Euclidean distance. Given
that our data has a non-gaussian and discrete distribution, we apply hamming distance instead of the Euclidean
distance.
Post the silhouette score and cost analysis on various K values (Refer Table 4). We found K=3 would be an
optimal number for our objective. Visualisation of clusters is still a question of research today, Nevertheless, to
get a fair idea and validity of our algorithm, we applied MCA(Multiple Correspondence Analysis) on the data and
applied it in order to project it on a 3D space. Multiple Correspondence Analysis tries to identify associations in
multiple categorical variables.[18] The parameters Init was set to Huang, K was set to 3 and n_init was set to 6 in
the K-modes parameter selection process.
Table 5. Explains the statistics obtained on each cluster. Next step was to identify the risk groups among these
cohorts. Cohort risk identification was made based on clinical knowledge and evidence of Covid studies. From
the inferences we drew from the above clusters we assigned subjective risks namely Low, Medium and High to
Cluster B, Cluster A, Cluster C respectively.
Cluster C happens to contain the symptomatic group of people with same exhibiting characteristics of the ones
that were investigated and observed globally till date. Hence, it is identified as a High risk group that is likely to
be symptomatic for Covid.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

V. INTERNAL VALIDATION
Internal validation of this model is essential to gauge the accuracy of it and test the sensitivity of the algorithm‚Äôs
ability to profile a new data point into its right risk group. To perform this validation, we analysed data from an
open source database that had high level summaries of the corona positive patients at the time of detection[17][23].
We used this information to simulate timelines for various scenarios from the onset of the symptoms till confirmed
date. We simulated about 1500 observations for 50 patients based on the age group, symptoms developed over a
timeline of 7 to 14 days. We essentially captured 3 major use cases that included, Covid symptoms with leading
indicators, Covid symptoms without leading indicators, Flu like symptoms with travel history, all of these
developed over 7 and 14 days. The objective was to identify if the model could distinguish between normal flu
and Covid symptoms that had lower incidence in the general population.
Fig 4. Shows results of the validation when run through the covid risk model.
The model was sensitive towards the Covid met indicator conditions and leading indicators, but there were few
false positives in example cases like, the risk was ‚ÄúHIGH‚Äù when it gave a more weightage to conditions like low
immunity and travel history. This is expected to improve when the model is re-trained on a bigger real world
dataset that has complex correlations and patterns.

VI.EXTERNAL VALIDATION
Covid19 Research Tool (C19RT) is a web application developed by the team at Cohere. The idea behind this web
application is to collect data from individuals for our research study and track their symptoms to identify the risk
of infection. This web application is for the public, and allows anybody to register and enter their symptoms at
least once a day for a period of 30 days. With prior research on Covid symptoms from various sources and our
clinical advisory board, we curated a questionnaire that was user friendly and targeted all levels of population.
We released this application in the month of May and have collected (still collecting) about 1000 plus data points
from 300 users. We have a privacy and security protocol in place to handle this collected information that is
anonymised and run through the Covid model in the backend.

VI a. C19RT WORKFLOW:
A new user registers into our application, after acknowledging the consent form. The designated user enters his
symptoms at least once a day on the web application(can be accessed on any digital device). This information is
then anonymised, run through the Covid risk algorithm which profiles this input with a similar group of people
and gives out the group/ risk category the person belongs to. When a change in the risk trend is observed, an alert
is emailed to the user. The entire application workflow is explained in Fig 5.
The collected data along with the risks were validated clinically and was compared against the targets generated
for each of them manually with clinical knowledge. The classification report and confusion matrix of this
validation is shown in Table.6 and fig 6 respectively.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

CONCLUSION:
We were successfully able to validate and deploy this model. Our research tool at present uses this model to
display a Covid risk score based on the user‚Äôs input.
Understanding Covid patterns in the symptomatic cases is still an ongoing challenge and subject of research.
Although, there are few sets of rules or pointers that could indicate the presence of the infection, just a rule based
solution wouldn‚Äôt be the right approach. Rule based decision systems tend to generate a lot of false positives and
have a relatively low precision. While, significantly larger real world data is definitely the key to better insights,
and results, our objective is to mimic the real world scenarios and identify patterns in order to catch these
symptoms earlier. The earlier the treatment, better the prognosis. Unsupervised learning like clustering can be a
powerful analysis in healthcare, because often in practice, clinicians tend to profile similar cases and conditions
along with other dimensions of a patient to land at an informed decision. Clustering that way, is mimicking this
concept, with only a superior ability to identify patterns across a huge dataset in terms of dimensions and size.
For the model to capture more complex correlation across the features and cohort patterns, our goal is to continue
to collect relevant data from a larger population to improve the algorithm, learn better patterns and reveal insights
that can help identify those with high risk of being infected with Covid19. This is just one part of the problem that
we try to solve. A bigger challenge is identifying the asymptomatic cases that go unidentified and unnoticed,
spreading widely in the population, described as community transmission by epidemiologists.

FUNDING:
This work was a self-funded project at Cohere-Med Inc.

REFERENCES
[1] https://www.healthcareitnews.com/news/synthetic-data-key-healthcare-clinical-and-business-intelligence
[2] Generating Multi-label Discrete Patient Records using Generative Adversarial Networks
[3] Real-valued (Medical) Time Series Generation with Recurrent Conditional GANs https://www.arxivvanity.com/papers/1706.02633/
[4] Generating Synthetic but Plausible Healthcare Record Datasets.https://arxiv.org/abs/1807.01514v1
[5] The validity of synthetic clinical data: a validation study of a leading synthetic data generator (Synthea)
using clinical quality measures https://doi.org/10.1186/s12911-019-0793-0
[6]Hall, Dylan, 2019, "10,000 Synthetic Medicare Patient Records", https://doi.org/10.7910/DVN/QDXLWR,
Harvard Dataverse, V1
[7]https://github.com/synthetichealth/synthea
[8]Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes
Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052‚Äì
2059. doi:10.1001/jama.2020.6775
[9]Pan A, Liu L, Wang C, et al. Association of Public Health Interventions With the Epidemiology of the
COVID-19 Outbreak in Wuhan, China. JAMA. 2020;323(19):1915‚Äì1923. doi:10.1001/jama.2020.6130
[10]https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/qa-coronaviruses
[11]Spinato G, Fabbris C, Polesel J, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With
SARS-CoV-2 Infection. JAMA. 2020;323(20):2089‚Äì2090. doi:10.1001/jama.2020.6771
[12]Elbattah, Mahmoud and Owen Molloy. ‚ÄúClustering-Aided Approach for Predicting Patient Outcomes with
Application to Elderly Healthcare in Ireland.‚Äù AAAI Workshops (2017).
[13]https://doi.org/10.1007/978-0-387-30164-8_425
[14]Z. Huang, ‚ÄúA Fast Clustering Algorithm to Cluster Very Large Categorical Data Sets in Data Mining‚Äù,
Proceedings of Data Mining and Knowledge Discovery, pp. 1-6, 1997.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

[15]Z. Huang, ‚ÄúExtensions to the K-means Algorithm for Clustering Large Data Sets with Categorical Value‚Äù,
Data Mining and Knowledge Discovery, Vol. 2, No. 3, pp. 283- 304, 1998.
[16]Rousseeuw, Peter. (1987). Rousseeuw, P.J.: Silhouettes: A Graphical Aid to the Interpretation and
Validation of Cluster Analysis. Comput. Appl. Math. 20, 53-65. Journal of Computational and Applied
Mathematics. 20. 53-65. 10.1016/0377-0427(87)90125-7.
[17]https://www.kaggle.com/rupsikaushik/covid19-patientlevel-data
[18]https://en.wikipedia.org/wiki/Multiple_correspondence_analysis
[19]Elbattah, Mahmoud & Molloy, Owen. (2017). Clustering-Aided Approach for Predicting Patient Outcomes
with Application to Elderly Healthcare in Ireland.
[20]Alashwal H, El Halaby M, Crouse JJ, Abdalla A, Moustafa AA. The Application of Unsupervised
Clustering Methods to Alzheimer's Disease. Front Comput Neurosci. 2019;13:31. Published 2019 May 24.
doi:10.3389/fncom.2019.00031
[21]Dube, Kudakwashe & Gallagher, Thomas. (2014). Approach and Method for Generating Realistic Synthetic
Electronic Healthcare Records for Secondary Use. 69-86. 10.1007/978-3-642-53956-5_6.
[22]Liao M, Li Y, Kianifard F, Obi E, Arcona S. Cluster analysis and its application to healthcare claims data: a
study of end-stage renal disease patients who initiated hemodialysis. BMC Nephrol. 2016;17:25. Published 2016
Mar 2. doi:10.1186/s12882-016-0238-2
[23] https://github.com/beoutbreakprepared/nCoV2019.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Fig 1. Approach to generate the faux dataset using available data and studies.

Fig 2. Representation of the real world Covid cases, prevalence disease statistics of Covid symptoms and
leading indicators for the infection.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Fig 3. Silhouette plots and clusters formed on different iterations and values of K. The clusters are
visualised post MCA(Multiple Correspondence Analysis) and were projected on a 3-Dimensional
space. K=3 Seems to the reasonable choice given the cost and silhouette scores.

Fig 4. Graphs showing the risk trend for six different timelines from the subset of the validation set.
Fig A is of a young, healthy person with no symptoms. Fig B is of a young person with covid criteria
symptoms with Leading Indicators developed over a week. Fig C is of a young person with flu like

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

symptoms(Not Covid criteria). Fig D is of an Old aged, Unhealthy(Comorbidities) patient with
Hypertension, Diabetes, Covid criteria along with leading indicators developed over a week. Fig E is of a
Young, Healthy person with travel history and low Immunity. Fig F is of a Middle aged,
Unhealthy(Comorbidities) person with Lung Disease ,Covid criteria with leading indicators developed over
1 week. Fig G is a Young, Healthy person with Covid criteria developed over 14 days. Fig H is a Middle
aged, Unhealthy(Comorbidities), Hypertension, Heart disease , Covid criteria without leading indicators
developed over 1 week.

Fig 5. The C19RT workflow step-wise.

Fig 6. Confusion Matrix obtained on validation set.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Covid criteria met definition
Presence of Fever
AND
Dry Cough
AND
Shortness of breath
AND
Fatigue
AND
Any 1 of the comorbidities
(
Heart disease, Diabetes, Lung disease, Hypertension, Kidney
)
Table 1. Features and rules considered for Covid criteria met
condition.

Leading Indicators for Covid
Chills

Loss of Taste and Smell

Muscle Ache

Chest Pain

Sore throat

Nausea

Conjunctivitis

Headache

Vomiting

Swollen Lymph Node

Diarrhea

Wheezing

Travel history

Low Immunity

Runny nose
Table 2. Features identified as Leading Signs for the infection.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Data Characteristics

n (%)

Total Number

N=10,00,000

Gender
Female

4,87,000 (48.7%)

Male

5,13,000 (51.3%)

Symptoms
Fever

232047 (23%)

Dry Cough

231724 (23.1%)

Shortness of Breath

232392 (23.2%)

Fatigue

240290 (24.0%)

Chills

180308 (18.0%)

Muscle Ache

201907 (20 %)

Sore throat

201690 (20.1%)

Conjunctivitis

96197 (9.1%)

Vomiting

164063 (16%)

Diarrhea

164236 (16.4%)

Travel history

163984 (16.3 %)

Runny nose

179910 (17.9 %)

Loss of Taste and Smell 125729 (12.5 %)
Chest Pain

107788 (10.7 %)

Nausea

199479 (19 %)

Headache

179889 (17.9 %)

Swollen Lymph Node

136131 (13.6 %)

Wheezing

210417 (21%)

Low Immunity

519633 (51.9 %)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Comorbidities
Heart Disease

246000 (24.6%)

Lung Disease

331400 (33.1%)

Kidney Disease

117243 (11.7 %)

Hypertension

506743 (50.6 %)

Diabetes

343600 (34.3 %)

Table 3. Data Description with all the features.

K Value

Cost

2

4442956

3

3946176

4

4176818

5

3007670

Table 4. Cost values on different K-values.

Features

Cluster A prevalence
n (%)

Cluster B prevalence
n (%)

Cluster C prevalence n(%)

N=10,00,000

6,01,458
(60%)

1,99,998
(19.9%)

1,98,544
(19.85%)

Fever

25403 (4.2%)

8102 (4.5%)

198542(98%)

Chest Pain

6603 (1.1%)

2037(1.02%)

99148(48%)

Chills

31166 (5.18)

9988(4.9%)

59563(30%)

Headache

60762(10.1%)

19832(9.92%)

99295(50%)

Nausea

60726(10.1%)

20097(10%)

118656(59.8)

Diarrhea

19036(3.16%)

5921(2.96%)

60601(31.1%)

Fatigue

31713(5.27%)

10038(5.02%)

198539(98%)

Change in Taste or smell

12758(2.12%)

3929(1.96%)

109042(54.9%)

Swollen Lymph Node

12856(2.14%)

3917(1.96%)

79417(40%)

Shortness of breath

25760(4.28%)

8095(4.05%)

198537(98%)

Cough

25287(4.2%)

7899(3.95%)

198538(97.8%)

Wheezing

61138(10.2%)

20000(10%)

129279(65%)

SYMPTOMS

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Sore throat

24000(3.99%)

7942(3.97%)

169748(85.5%)

Vomiting

18893(3.14%)

6067(3.03%)

60612(32%)

Muscle Ache

24030(4%)

7986(3.99%)

169891(85%)

Runny Nose

30937(5.14%)

9919(4.96%)

139054(70%)

Conjunctivitis

12720(2.11%)

3950(1.98%)

39727(21%)

Travel History

19092(3.17%)

6061(3.03%)

138831(70%)

Diabetes

207771(34.5%)

68711(34.4%)

67118(33.8%)

Heart Disease

73861(12.3%)

24071(12%)

148068(74.6%)

Hypertension

401465(66.7%)

0(0%)

105278(53%)

Kidney Disease

13930(2.32%)

4369(2.18%)

34369(17.1%)

Lung Disease

222371(37%)

74660(37.3%)

98944(49.8%)

Low Immunity

401466(66.7%)

0(0%)

118167(60%)

COMORBIDITIES

Table 5. Cluster statistics and description after applying K-modes.

Clusters

Recall

Precision

Cluster A (Medium Risk)

72%

82%

Cluster B (Low Risk)

85%

85%

Cluster C (High Risk)

92%

84%

Table 6. Risk Stratification analysis on the real world data.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20137950; this version posted June 25, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

